Trials

PARAGON – the study that drove ANZGOG’s position at the forefront of innovative trial designs

Led by ANZGOG co-founder Professor Michael Friedlander AM, PARAGON was one of ANZGOG's first practice-changing studies. The publications arising from the insights and data collected because of this pivotal trial continue to contribute to research on [...]

PARAGON – the study that drove ANZGOG’s position at the forefront of innovative trial designs2023-10-18T11:45:30+11:00

ITTACc – ANZGOG’s latest cervical cancer study, incorporating ANZGOG’s first teletrial cluster!

A Phase II Trial of Tislelizumab in combination with Sitravatinib for Recurrent/Metastatic Cervical Cancer after Platinum-Based Chemotherapy. The ITTACc study is an ANZGOG-developed trial led in Australia by A/Prof Jeffrey Goh from the Royal [...]

ITTACc – ANZGOG’s latest cervical cancer study, incorporating ANZGOG’s first teletrial cluster!2023-10-18T11:49:12+11:00

ANZGOG’s Endometrial Cancer Study Awarded $1.27 Million in Funding from the MRFF Grant

ANZGOG’s TAPER Study has received $1.27 million in funding from the Australian Government’s Medical Research Future Fund (MRFF) which aims to improve the health and wellbeing of Australians by supporting medical research and innovation.  [...]

ANZGOG’s Endometrial Cancer Study Awarded $1.27 Million in Funding from the MRFF Grant2023-10-18T11:50:42+11:00

PEACE trial opens to recruitment

ANZGOG’s new study for patients with advanced gynaecological cancer, PEACE, has officially opened to recruitment after activating its first site, Canberra Hospital. Led by Principal Investigator Dr Alison Davis in Australia, the international study [...]

PEACE trial opens to recruitment2023-10-18T12:01:14+11:00
Go to Top